《生物加工过程》被美国BIOSIS Previews收录

BIOSIS Previews由美国生物科学信息服务社(BIOSIS)出版,是世界上最大的关于生命科学的文摘索引数据库,隶属于汤姆森科技信息集团。汤姆森科技信息集团隶属于汤姆森公司(The Thomson Corporation),旗下包括ISI,Derwent,BIOSIS等许多著名的信息服务品牌。可以参阅网站:http://www.thomsonscientific.com.cn该库包括生物学文摘Biological Abstracts(R)所收录期刊以及Biological Abstracts/RRM(R)所收录的会议、报告、评论、图书、专利等多种出版类型文献。学科覆盖:生物学、生物化学、生物技术、植物学、医学、药理学、动物学、…     

征稿启事

正《生物加工过程》(2003年创刊,双月刊)是由南京工业大学主办、中国生物工程学会和中国化工学会生物化工专业委员会协办、国内外公开发行的综合性中文学术期刊,国际刊号ISSN1672-3678,国内统一刊号CN32-1706/Q。本刊目前被《中国科技核心期刊》《科学引文数据库》(SCD)、《中国学术期刊综合评价数据库》《中国期刊全文数据库》《中国生物学文摘》、RCCSE中国核心学术期刊(A)、《万方数据资源系统数字化期刊》、台湾华艺思博网等中文数据库和美国《生物学文摘(预评)》(BP,BIOSIS Previews)、美国《化学文摘(网络版)》     

征稿启事

<正>《生物加工过程》(2003年创刊,双月刊)是由南京工业大学主办、中国生物工程学会和中国化工学会生物化工专业委员会协办、国内外公开发行的综合性中文学术期刊,国际刊号ISSNI672-3678,国内统一刊号CN32—1706/Q。本刊目前被《中国科技核心期刊》、《科学引文数据库》(SCD),《中国学术期刊综合评价数据库》《中国期刊全文数据库》《中国生物学文摘》、RCCSE中国核心学术期刊(A),《万方数据资源系统数字化期刊》、台湾华艺思博网等中文数据库和美国《生物学文摘(预评)》(BP,BIOSIS Previews)、美国《化学文摘(网络版)》     

征稿简则

正简介:《中国科学:生命科学》是中国科学院主管、中国科学院和国家自然科学基金委员会共同主办的生命科学类综合性学术期刊,力求及时报道生物学、医学、农学和生态学领域的基础研究与应用研究方面具有重要意义的成果.由《中国科学》杂志社出版,月刊,每月20日出版.英文版:SCIENCE CHINA Life Sciences(英文版)是《中国科学:生命科学》的姊妹刊.收录情况:《中国科学:生命科学》被《中国科学引文数据库》、《中国科技论文与引文数据库》、《中国期刊全文数据库》、《中文核心期刊要目总览》等收录. SCIENCE CHINA Life Sciences被SCI, MEDLINE, BIOSIS, CA等收录.     

征稿简则

正简介:《中国科学:生命科学》是中国科学院主管、中国科学院和国家自然科学基金委员会共同主办的生命科学类综合性学术期刊,力求及时报道生物学、医学、农学和生态学领域的基础研究与应用研究方面具有重要意义的成果.由《中国科学》杂志社出版,月刊,每月20日出版.英文版:SCIENCE CHINA Life Sciences(英文版)是《中国科学:生命科学》的姊妹刊.收录情况:《中国科学:生命科学》被《中国科学引文数据库》、《中国科技论文与引文数据库》、《中国期刊全文数据库》、《中文核心期刊要目总览》等收录. SCIENCE CHINA Life Sciences被SCI, MEDLINE, BIOSIS, CA等收录.     

征稿简则

正简介:《中国科学:生命科学》是中国科学院主管、中国科学院和国家自然科学基金委员会共同主办的生命科学类综合性学术期刊,力求及时报道生物学、医学、农学和生态学领域的基础研究与应用研究方面具有重要意义的成果.由《中国科学》杂志社出版,月刊,每月20日出版.英文版:SCIENCE CHINA Life Sciences(英文版)是《中国科学:生命科学》的姊妹刊.收录情况:《中国科学:生命科学》被《中国科学引文数据库》、《中国科技论文与引文数据库》、《中国期刊全文数据库》、《中文核心期刊要目总览》等收录. SCIENCE CHINA Life Sciences被SCI, MEDLINE, BIOSIS, CA等收录.     

Cell Research期刊征订单

CellResearch为中国科学院上海生命科学研究院主办,以全英文刊登国内外细胞生物学及其相关领域的原创性研究论文、综述、快报和述评的国际性期刊。已被Index Medicus,Medline,SCI（SciSearch ISI Web of Science）,BIOSIS,CA,VINIT以及《中国科学引文数据库》、《万方数据库》（光盘版,网络版）、《中国英文版科技期刊数据库》、《中文科技期刊数据库》、《中国学术期刊》（光盘版,网络版）、     

征稿简则

正简介:《中国科学:生命科学》是中国科学院主管、中国科学院和国家自然科学基金委员会共同主办的生命科学类综合性学术期刊,力求及时报道生物学、医学、农学和生态学领域的基础研究与应用研究方面具有重要意义的成果.由《中国科学》杂志社出版,月刊,每月20日出版.英文版:SCIENCE CHINA Life Sciences(英文版)是《中国科学:生命科学》的姊妹刊.收录情况:《中国科学:生命科学》被《中国科学引文数据库》、《中国科技论文与引文数据库》、《中国期刊全文数据库》、《中文核心期刊要目总览》等收录. SCIENCE CHINA Life Sciences被SCI, MEDLINE, BIOSIS, CA等收录.     

新版STN~?为知识产权专业人员提供核心生物医学信息及专利内容

<正>美国化学文摘社和德国卡尔斯鲁厄专业情报中心近日宣布,新版STN检索平台正式上线。新版本中的数据库内容,包括生物医学数据库BIOSIS、MEDLINE和EmbaseTM,互补性的生命科学数据库CABA和FSTA,以及比Classic STN覆盖面更广泛的全球专利全文数据库,因而可为检索者提供更多所需信息。美国化学文摘社市场营销副总裁Christine McCue介绍,新版STN是一套现代高效的科研解决方案。新增的生物医学和专利数据库将会使更     

欢迎订阅《生物技术》杂志

正《生物技术》杂志是中文核心期刊、RCCSE中国核心学术期刊、中国农业核心期刊、中国生物学核心期刊,被生物学数据库(BIOSIS)、生物学文摘(BA)、化学文摘(CA)、中国科学引文数据库(CSCD)、《核心期刊要目总览》、中国核心期刊遴选数据库、中国知网等近20多家国内外重要检索系统收录。是涉及生物工程、生物技术、微生物及生命科学相关领域的专业学术刊期     

Erratum to: Pick of the Year 2014

In June 2015, Thomson Reuters informed our publisher Springer that the Journal of Cell Communication and Signaling, the official journal of the International CCN Society, « had been selected for coverage in Thomson Reuter’s products and services. Beginning with V. 1 (1) 2007, this publication would be indexed and abstracted in Science Citation Index Expanded (also known as SciSearch), Journal Citation Reports/Science Edition, Biological Abstracts and BIOSIS Previews ». In this fall editorial I briefly revisit a few milestones of the JCCS life since it was first created in 1988, with the deep and genuine willingness to help in the dissemination, in the highly competitive world of publishing, of the best quality science regarding the roles of CCN proteins in signaling.     

如何利用BIOSIS Previews查询微生物学文献

为了帮助国内科技人员有效地利用Internet网络查找微生物学的相关信息,对世界著名的生命科学数字化信息资源数据库BIOSISPreviews的基本情况、界面结构及使用方法等进行介绍。     

Associations between tumor necrosis factor alpha gene polymorphism and sarcoidosis: a meta-analysis

Published studies regarding the association between tumor necrosis factor alpha (TNF-α) gene polymorphism and sarcoidosis risk are inconsistent. In order to clarify this association, we performed a meta-analysis of case–control studies with available data. PubMed, EMBASE and BIOSIS Previews were comprehensively searched to identify relevant studies. Twelve case–control studies in 11 articles involving 3,218 participants were included in the meta-analysis to assess the association between TNF-α gene polymorphism and susceptibility to sarcoidosis. We estimated the pooled odds ratio (OR) with its 95 % confidence intervals (95 % CI) to explore the potential association. Our meta-analysis results suggested that TNF-α-308G/A AA/AG genotype increased sarcoidosis risk, in Asian and Caucasian ethnicity, and in sarcoidosis with Löfgren syndrome. No association was found between TNF-α-238G/A, TNF-α-857C/T polymorphism and sarcoidosis risk. In conclusion, our meta-analysis indicated that AG/GG genotype of TNF-α-308G/A are associated with increased sarcoidosis risk.     

Insulin Glargine Use During Pregnancy

ObjectiveTo review the literature regarding the use of insulin glargine during pregnancy, specifically addressing the issues and concerns surrounding mitogenicity, placental transfer, and maternal and fetal safety.MethodsWe performed a systematic literature search using MEDLINE and BIOSIS Previews up to March 2011. Additional studies were identified by hand-searching reference lists from original articles. Inclusion was limited to studies and abstracts in the English language.ResultsA total of 23 reports with 1001 pregnancies managed with insulin glargine contained relevant information regarding the maternal and fetal safety of its use during pregnancy. Insulin glargine does not appear to have enhanced mitogenic activity when compared with the mitogenic activity of native human insulin. The transplacental transfer of insulin glargine appears to be negligible, although it is possible that antibody-bound insulin glargine may gain access to the fetal compartment. The available data suggest that there are no identifiable, consistent adverse maternal or fetal outcomes with the use of insulin glargine during pregnancy, including during the first trimester.ConclusionsUse of insulin glargine during pregnancy should be seriously considered in uncontrolled diabetes during pregnancy and in those patients taking insulin glargine before conception, because the benefits from improved glycemic control would be expected to outweigh any, as yet, unproven risks of insulin glargine exposure.(Endocr Pract. 2011;17:448-455)     

IL6 gene polymorphisms and susceptibility to colorectal cancer: a meta-analysis and review

A number of case-control studies were conducted to investigate the association of IL6 gene polymorphisms with colorectal cancer (CRC). However, the results were not always consistent. We performed a systematic review and meta-analysis to examine the association between the IL6 gene polymorphisms and CRC. Data were collected from the following electronic databases: PubMed, EMBASE, Web of Science, BIOSIS Previews, HuGENet, and Chinese Biomedical Literature Database, with the last report up to July 2011. A total of 17 studies involving 4 SNPs were included (16 for rs1800795, 2 for rs1800796, 2 for rs1800797, and 1 for rs13306435). Overall, no significant association of these polymorphisms with CRC was found in heterozygote comparisons as well as homozygote comparison, dominant genetic model and recessive model. In subgroup analysis, among studies using population-based controls, fulfilling Hardy-Weinberg equilibrium, or using Taqman genotyping method, we did not find any significant association. However, the rs1800795 C allele was significantly associated with reduced risk for CRC among persons who regularly or currently took NSAIDs (four studies, OR = 0.750; 95 % CI, 0.64-0.88; P = 0.474 for heterogeneity test), and with increased risk for CRC among persons who drank (one study, OR = 1.97; 95 % CI, 1.32-2.94). Individuals with the rs1800795 C allele in the IL6 gene have a significantly lower risk of CRC, but in the setting of NSAIDs use. Further studies are merited to assess the association between the IL6 gene polymorphisms and CRC risk among persons who take NSAIDs, drink or smoke, etc.     

Methylenetetrahydrofolate reductase gene C677T,A1298C polymorphisms and pre-eclampsia risk: a meta-analysis

To determine whether methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C polymorphisms are associated with pre-eclampsia susceptibility. Literature searches of the Pubmed, Embase, BIOSIS Previews and Web of Science were conducted to identify all eligible articles up to January 18th, 2013. The pooled odds ratios (ORs) with 95 % confidence intervals (CIs) of five genetic models were calculated by fixed-effects or random-effects model. Publication bias, subgroup analysis, meta-regression and sensitivity analysis were also performed. A number of 49 studies including 51 samples consisted of 18,009 subjects (6,238 patients and 11,771 controls) were finally included. MTHFR C677T allele (TT or CT) carriers were 1.12 times more likely to develop pre-eclampsia (95 % CI 1.04–1.21) compared with 677CC homozygous individuals. Similar results were obtained under other genetic models. Restricted to severe pre-eclampsia, there was an increased risk for 677TT homozygotes compared with 677CC homozygotes (OR 1.43; 95 % CI 1.12–1.83). Subgroup analysis revealed a significant positive association between the C677T polymorphism (TT or CT) and pre-eclampsia in Asians (OR 1.41; 95 % CI 1.11–1.79) and white population (OR 1.14; 95 % CI 1.03–1.25). Meta-regression showed that study population, blinded genotyping, matching of cases and controls were not substantial sources of heterogeneity. For the MTHFR A1298C, ORs for all genetic models yielded a null association. This meta-analysis suggests that the MTHFR 677T allele might be associated with increased pre-eclampsia risk in Asian and white ethnicity and the subgroup of severe pre-eclampsia, while no association is observed between the MTHFR A1298C polymorphism and pre-eclampsia.     

Long acting β2 agonists for stable chronic obstructive pulmonary disease with poor reversibility: a systematic review of randomised controlled trials

Background

The long acting β2-agonists, salmeterol and formoterol, have been recommended, by some, as first line treatment of stable chronic obstructive pulmonary disease (COPD). We reviewed evidence of efficacy and safety when compared with placebo or anticholinergic agents in patients with poorly reversible COPD.

Methods

After searching MEDLINE, EMBASE, HealthSTAR, BIOSIS Previews, PASCAL, ToxFile, SciSearch, the Cochrane Library, and PubMed, as well as Web sites, selected journals, reference lists, and contacting drug manufacturers, two reviewers independently screened reports of randomised controlled trials of parallel or crossover design lasting four weeks or longer and including patients with a forced expiratory volume in one second (FEV1) ≤ 75% of predicted, a ratio of FEV1 to forced vital capacity (FVC) ≤ 88% of predicted, and < 15% improvement from baseline FEV1 after a dose of a β2 agonist. We included trials comparing salmeterol or formoterol with placebo or with ipratropium bromide and reporting one of these outcomes: lung function; exercise capacity; quality of life scores; dyspnea; exacerbations; rescue inhaler use; incidence of tachycardia, hypokalemia, or dry mouth. Two reviewers assessed the quality of included reports using the Jadad scale and allocation concealment, and abstracted data.

Results

Twelve trials satisfied our inclusion criteria; eight were high quality (Jadad score >2) and four were low quality (≤ 2). The adequacy of allocation concealment was unclear in all of them. We did not perform a meta-analysis due to differences in trial design and how outcomes were reported. Two trials comparing salmeterol with ipratropium did not detect differences; one trial comparing formoterol and ipratropium described greater improvement with formoterol in morning PEFR (15.3 versus 7.1 l/min, p = 0.040). Of twelve trials comparing long acting β2 agonists with placebo, six reported no improvement in exercise capacity, eleven reported improvements in FEV1 lung function (one reported no improvement), six reported less rescue inhaler usage (one reported no difference) and five reported improved dyspnea scores (two reported no improvement). Differences in quality of life were detected in one salmeterol trial ; however, two salmeterol, and one formoterol trial reported no differences. Adverse effects of interest were not reported.

Conclusion

In terms of clinical outcomes and safety, we could not find convincing evidence that salmeterol and formoterol have demonstrated advantages to ipratropium, a less expensive drug, for patients with stable COPD and poor reversibility. Compared to placebo, we found evidence of reduced rescue inhaler usage and improved spirometric outcomes without a significant impact on quality of life or exercise capacity.     

Association between β2-Adrenoceptor Gene Polymorphisms and Asthma Risk: An Updated Meta-Analysis

Background

Evidence is increasingly accumulated about multiple roles for the β2-adrenoceptor gene in asthma. The results were inconsistent partly due to small sample sizes. To assess the association between β2-adrenoceptor gene polymorphisms and asthma risk, a meta-analysis was performed.

Methods

We comprehensively searched the PubMed, EMBASE, BIOSIS Previews databases and extracted data from all eligible articles to estimate the association between β2-adrenoceptor gene polymorphisms and asthma risk. The pooled odds ratio (OR) with 95% confidence intervals (CIs) were calculated.

Results

Thirty-seven studies involving 6648 asthma patients and 15943 controls were included in the meta-analysis. Overall, significant associations were found in allelic genetic model (OR = 1.06, 95% CI = 1.01∼1.12), recessive genetic model (OR = 1.11, 95% CI = 1.02∼1.21) for Arg/Gly16. Stratified by ethnicity and age, significant associations were also found in Asian population in allelic genetic model, recessive genetic model and addictive model. For Gln/Glu27, no significant association was found when we combined all eligible studies. Age stratification showed significant associations in adults in allelic genetic model and recessive genetic model, but no significant association was found among Asians and Caucasians in ethnicity stratification.

Conclusions

This meta-analysis implied that the β2-adrenoceptor Arg/Gly16 polymorphism was likely to contribute to asthma risk in Asian population. Gln/Glu27 polymorphism might be a contributor to asthma susceptibility for adults.     

Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis

IntroductionPatients with rheumatoid arthritis (RA) are at an increased risk of malignancies compared with the general population. This has raised concerns regarding these patients, particularly with the widespread use of immunomodulating therapies, including biologic disease-modifying antirheumatic drugs (DMARDs). We performed a systematic literature review and analysis to quantify the incidence of malignancies in patients with RA and the general population to update previously published data.MethodsA literature search was conducted that was consistent with and similar to that in a meta-analysis published in 2008. MEDLINE, BIOSIS Previews, Embase, Derwent Drug File and SciSearch databases were searched using specified search terms. Predefined inclusion criteria identified the relevant observational studies published between 2008 and 2014 that provided estimates of relative risk of malignancy in patients with RA compared with the general population. Risk data on overall malignancy and site-specific malignancies (lymphoma, melanoma and lung, colorectal, breast, cervical and prostate cancer) were extracted. The standardized incidence ratios (SIRs; a measure of risk) relative to the general population were evaluated and compared with published rates.ResultsA total of nine publications met the inclusion criteria. Seven of these reported SIRs for overall malignancy; eight for lymphoma, melanoma, and lung, colorectal and breast cancer; seven for prostate cancer; and four for cervical cancer. Compared with those in the general population, the SIR estimates for patients with RA suggest a modest increased risk in overall malignancy, as previously observed. Patients with RA continued to show an increased risk of lymphoma and lung cancer compared with the general population. Overall, SIR estimates for colorectal and breast cancers continued to show a decrease in risk, whereas cervical cancer, prostate cancer and melanoma appeared to show no consistent trend in risk among patients with RA compared with the general population.ConclusionsThe additional data evaluated here are consistent with previously reported data. Patients with RA are at an increased risk of lung and lymphoma malignancies compared with the general population. Quantifying differences in malignancy rates between non-biologic and biologic DMARD-treated patients with RA may further highlight which malignancies may be related to treatment rather than to the underlying disease.